Cargando…
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
PATIENTS AND METHODS: Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ h...
Autores principales: | Radovich, Milan, Kiel, Patrick J., Nance, Stacy M., Niland, Erin E., Parsley, Megan E., Ferguson, Meagan E., Jiang, Guanglong, Ammakkanavar, Natraj R., Einhorn, Lawrence H., Cheng, Liang, Nassiri, Mehdi, Davidson, Darrell D., Rushing, Daniel A., Loehrer, Patrick J., Pili, Roberto, Hanna, Nasser, Callaghan, J. Thomas, Skaar, Todd C., Helft, Paul R., Shahda, Safi, O’Neil, Bert H., Schneider, Bryan P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302930/ https://www.ncbi.nlm.nih.gov/pubmed/27447854 http://dx.doi.org/10.18632/oncotarget.10606 |
Ejemplares similares
-
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Shahda, Safi, et al.
Publicado: (2016) -
Adjuvant therapy for endometrial cancer
por: DeLeon, Maria C., et al.
Publicado: (2014) -
Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
por: Kollipara, Revathi, et al.
Publicado: (2017) -
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study
por: Gbolahan, Olumide B., et al.
Publicado: (2019) -
A phase II study of buparlisib in relapsed or refractory thymomas
por: Abu Zaid, Mohammad I., et al.
Publicado: (2022)